Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway

Zi, Xin; Zhang, Guoqiang; Qiu, Shichao

doi:10.1080/15592294.2021.1890873

Cited by 10 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HGF is known to activate the tumor-promoting PI3K/Akt pathway in other cancers. As expected, the group saw a negative correlation between LINC00619 and HGF-PI3K/Akt expression [53]. Another study carried out by Yan et al further evaluated the upregulated expression and molecular function of the lncRNA PVT1 in OS by exploring what role it plays in the PVT1/mi8R-486 axis.…”

Section: Non-coding Rnamentioning

confidence: 64%

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review

Twenhafel,

Moreno,

Punt

et al. 2023

Cells

View full text Add to dashboard Cite

Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. While clinical outcomes have improved, the 5-year survival rate is only around 60% if discovered early and can require debilitating treatments, such as amputations. A better understanding of the disease could lead to better clinical outcomes for patients with osteosarcoma. One promising avenue of osteosarcoma research is in the field of epigenetics. This research investigates changes in genetic expression that occur above the genome rather than in the genetic code itself. The epigenetics of osteosarcoma is an active area of research that is still not fully understood. In a narrative review, we examine recent advances in the epigenetics of osteosarcoma by reporting biomarkers of DNA methylation, histone modifications, and non-coding RNA associated with disease progression. We also show how cancer tumor epigenetic profiles are being used to predict and improve patient outcomes. The papers in this review cover a large range of epigenetic target genes and pathways that modulate many aspects of osteosarcoma, including but not limited to metastases and chemotherapy resistance. Ultimately, this review will shed light on the recent advances in the epigenetics of osteosarcoma and illustrate the clinical benefits of this field of research.

show abstract

Section: Non-coding Rnamentioning

confidence: 64%

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review

Twenhafel,

Moreno,

Punt

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Furthermore, FER1L4 knockdown increases PI3K levels and AKT phosphorylation, consequently facilitating cell apoptosis and inhibiting EMT ( Ye et al, 2019 ). Conversely, LINC00619 has been shown to inhibit the proliferation, migration, and invasion of OS cells by inactivating the HGF-mediated PI3K/AKT signaling pathway ( Zi et al, 2022 ). Other lncRNAs such as UCA1( Ma et al, 2019 ), LINC00968( Liu et al, 2018 ), LINC00628( He et al, 2018 ), HULC ( Kong and Wang, 2018 ), CCAT2 ( Liu J. et al, 2019 ), PVT1 ( Sun et al, 2019 ), LOXL1-AS1 ( Chen et al, 2019 ), CBR3-AS1 ( Yao et al, 2022 ) and DBH-AS1 ( Liu ZB.…”

Section: Role Of Lncrnas In Os Oncogenesis and Progressionmentioning

confidence: 99%

Emerging roles of long non-coding RNAs in osteosarcoma

Liao,

Wei,

Zhou

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Osteosarcoma (OS) is a highly aggressive and lethal malignant bone tumor that primarily afflicts children, adolescents, and young adults. However, the molecular mechanisms underlying OS pathogenesis remain obscure. Mounting evidence implicates dysregulated long non-coding RNAs (lncRNAs) in tumorigenesis and progression. These lncRNAs play a pivotal role in modulating gene expression at diverse epigenetic, transcriptional, and post-transcriptional levels. Uncovering the roles of aberrant lncRNAs would provide new insights into OS pathogenesis and novel tools for its early diagnosis and treatment. In this review, we summarize the significance of lncRNAs in controlling signaling pathways implicated in OS development, including the Wnt/β-catenin, PI3K/AKT/mTOR, NF-κB, Notch, Hippo, and HIF-1α. Moreover, we discuss the multifaceted contributions of lncRNAs to drug resistance in OS, as well as their potential to serve as biomarkers and therapeutic targets. This review aims to encourage further research into lncRNA field and the development of more effective therapeutic strategies for patients with OS.

show abstract

“…However, in combination with other tumor markers like carbohydrate antigen 19-9 (CA 19-9), elevated ALP levels may be used to aid in diagnosing pancreatic cancer ( 29 , 30 ). While the exact role of ALPs in pancreatic cancer is still unknown, some studies have suggested that ALP may be involved in promoting tumor growth and invasion ( 31 - 33 ). In animal studies, inhibiting ALP has been found to reduce the progression and metastasis of pancreatic cancer ( 34 ).…”

Section: Alps In Pancreatic Cancermentioning

confidence: 99%

Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?

Jiang,

Zeng,

2023

Transl Cancer Res

View full text Add to dashboard Cite

Alkaline phosphatase (ALP) is a group of enzymes that catalyze hydrolysis of phosphate esters at an alkaline pH, resulting in the generation of inorganic phosphate. These enzymes are widely distributed, and their activity is found in various tissues including bone, liver, intestine, and placenta. However, abnormalities in ALP expression and activity have been observed in certain types of cancer. In some cases, elevated serum levels of ALP are observed in patients with liver and bone metastasis. In other cases, increased levels of ALP have been observed in patients with pancreatic and lung cancer. On the other hand, low expression of ALP has also been associated with poor prognosis in patients with certain types of tumors, including colorectal cancer (CRC), breast cancer, and non-small cell lung cancer (NSCLC). In these cases, low ALP activity may be associated with decreased differentiation of cancer cells and increased cancer cell proliferation. Overall, the role of ALP in cancer is complex and context-dependent. This article reviews application progress of ALP in cancer, and we hypothesize that ALP might be a potential tumor biomarker, combined detection of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), bone-specific alkaline phosphatase (BSAP), carbohydrate antigen 19-9 (CA 19-9), lactate dehydrogenase (LDH) and ALP isozymes levels can be used for more accurate diagnosis of a particular tumor. Further research is needed to better understand the mechanisms underlying ALP dysregulation in cancer and to identify potential therapeutic targets.

show abstract

Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway

Cited by 10 publications

References 37 publications

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review

Emerging roles of long non-coding RNAs in osteosarcoma

Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?

Contact Info

Product

Resources

About